Citius Pharmaceuticals, Inc.CTXR

時価総額
$9066.8万
PER
2011年
9月30日
2012年
9月30日
2013年
9月30日
2015年
9月30日
2016年
9月30日
2018年
9月30日
2019年
9月30日
2020年
9月30日
2021年
9月30日
2022年
9月30日
Cash and cash equivalents212135-676,137294,35198147042
Prepaid expenses---60,000598,48457,73248,111122,23733
Total Current Assets212135-736,137892,835108147345
Property and equipment, net----3,7421,4835901,5777,0234,100
Operating lease right-of-use asset, net-------986,204822,828646,074
Deposits----2,1672,16757,09357,09338,06238,062
In-process research and development-----1919195959
Goodwill----222999
Total Other Assets---5,401212121296969
Total Assets212135-741,53822312944142114
Accounts payable906-11,474559,150909,15623211
Accrued expenses3,9504,150-8,260958,101181,657246,225164,040621,9601
Accrued compensation----903,25011222
Operating lease liability-------158,999177,237196,989
Total Current Liabilities24,05345,98214,6941535445
Deferred tax liability-------556
Operating lease liability – non current-------855,471678,234481,245
Total Liabilities-------101011
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding----------
Common stock - $0.001 par value; 400,000,000 shares authorized; 146,211,130 and 145,979,429 shares issued and outstanding at September 30, 2022 and 2021, respectively18,00018,00018,00034,11873,13816,19928,93055,577145,979146,211
Additional paid-in capital--62,5228346880104228232
Accumulated deficit----9,040,549-17,336,247-40,257,838-55,819,982-70,593,867-96,047,821-129,688,467
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity-23,841-45,847-14,694-635,21317282434133103
Non-controlling interest--------600,380600,380
Total Equity--------133103
Total Liabilities and Equity212135-741,53822312944142114